secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVS HEALTH Corp (CVS)
CIK:        0000064803
Form:       8-K
Filed at:   2023-08-23T23:59:59+00:00
Accession:  0000947871-23-000898
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVS Health launches Cordavis subsidiary; first biosimilar Hyrimoz at >80% lower list price than Humira
--------------------------------------------------------------------------------

- Launched Cordavis, a wholly owned subsidiary to commercialize and co-produce biosimilar products in the U.S.
- First product: Cordavis private-label Hyrimoz (adalimumab-adaz) from Sandoz, launching Q1 2024.
- List price of Cordavis Hyrimoz will be more than 80% lower than current Humira list price.
- U.S. biosimilar market projected to grow from <$10B in 2022 to >$100B by 2029.
- CVS CFO states Cordavis will help ensure sufficient biosimilar supply and reduce drug costs for consumers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/64803/000094787123000898/0000947871-23-000898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/64803/000094787123000898/ss2413675_8k.htm
  HTML page:      https://secwatch.observer/filing/0000947871-23-000898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer